Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer

BACKGROUND: Pharmacological inhibition of the immune-checkpoint molecule CD47 has shown promising results in preclinical small-cell lung cancer (SCLC) models, whereas anti-programmed death-ligand 1 (PD-L1) inhibitors have been recently implemented in the standard of care of advanced-stage SCLC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, C., Lantos, A., Megyesfalvi, Z., Egger, F., Hoda, M.A., Mosleh, B., Klikovits, T., Oberndorfer, F., Timelthaler, G., Ferencz, B., Fillinger, J., Schwendenwein, A., Querner, A.S., Boettiger, K., Renyi-Vamos, F., Hoetzenecker, K., Laszlo, V., Schelch, K., Dome, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808447/
https://www.ncbi.nlm.nih.gov/pubmed/36399951
http://dx.doi.org/10.1016/j.esmoop.2022.100631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808447/
https://www.ncbi.nlm.nih.gov/pubmed/36399951
http://dx.doi.org/10.1016/j.esmoop.2022.100631

Ejemplares similares